Dayvigo (lemborexant) is a novel orexin receptor antagonist used for the treatment of insomnia, and its access channels and medication safety have attracted significant attention.

What Are the Purchase Channels for Dayvigo (Lemborexant)?

Overseas Purchase

Patients may choose to consult and purchase Dayvigo at hospital pharmacies or legitimate drugstores in countries or regions where the medication has been approved for marketing.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Dayvigo (Lemborexant)

Contraindication Screening

This medication is explicitly contraindicated in patients with narcolepsy.

Before using the medication, a professional doctor must rule out the possibility of such a disease.

Medication Warnings for Special Populations

Patients with hepatic impairment: The maximum recommended dose for patients with moderate hepatic impairment (Child-Pugh B) is 5 mg, and the medication is not recommended for patients with severe hepatic impairment (Child-Pugh C).

Checking for Drug Interactions

Avoid concurrent use with strong or moderate CYP3A inhibitors (e.g., itraconazole, clarithromycin) and inducers (e.g., rifampicin, carbamazepine).

Dosage and Administration Guidelines

The recommended dose is 5 mg, administered no more than once per night, taken immediately before bedtime. It is essential to ensure that there are at least 7 hours of planned sleep time before the intended wake-up time.

Depending on clinical response and tolerability, the dose may be increased to the maximum recommended dose of 10 mg. When co-administered with weak CYP3A inhibitors, the maximum recommended dose is 5 mg.

Authenticity Verification of Dayvigo (Lemborexant)

Identification of Physical Characteristics

5 mg tablets: Light yellow, round, biconvex film-coated tablets, engraved with "5" on one side and "LЄM" on the other side.

Packaging Information Verification

Authentic Dayvigo is packaged in child-resistant medicine bottles. The label information is complete and clear, including key details such as the drug name, strength, batch number, and expiration date.

Verification Through Official Channels

Query the drug approval information on the official website of the U.S. FDA and verify the qualification of the manufacturer, Eisai Inc.

Checking the Drug Code

Authentic packaging is printed with the National Drug Code (NDC). The NDC for the 5 mg strength falls under the 62856-405 series, and the NDC for the 10 mg strength falls under the 62856-410 series.

Understanding Pharmacological Properties

As an orexin receptor antagonist, authentic Dayvigo inhibits wakefulness drive by blocking the binding of orexin A and orexin B to the OX1R and OX2R receptors.